drugset / Trial / NCT02237859

Vancomycin Prophylaxis in Recurrent Clostridium Difficile Infection

NCT02237859

Phase 4 Unknown 140 enrolled Corewell Health West
NaSingle-groupTriple-blindPrevention

Summary

We are doing this research study to determine if taking vancomycin in addition to a broad-spectrum antibiotic will decrease the chance of developing recurrent Clostridium difficile infection.

Timeline

Start
2014-08
Primary completion
2016-08
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Vancomycin Other / unclassified 125 mg Oral